BETA · Beta Drugs Limited · Financials
Market Cap
20.21B INR
Shares
11.12M
Volume · Nov 13
11.61K
Avg daily vol (3M)
40.37K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
3.85B
+6.2%
FY2026
Net Income
414.83M
-2.2%
FY2026
Operating Cash Flow
372.86M
+18%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 |
|---|---|---|---|
| INR | 4.44B | 3.85B | 3.62B |
| INR | 181.42M | 171.53M | 125.14M |
| INR | 125.81M | 153.11M | 69.89M |
| INR | 701.24M | 543.94M | 569.69M |
| INR | 167.88M | 129.11M | 145.5M |
| INR | 90.49M | 414.83M | 424.18M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.